Therapeutic effects of dasatinib in mouse model of multiple sclerosis

References

• Love S. Demyelinating diseases. J Clin Pathol 2006;59:1151–1159
   PubMed Web of Science ®Google Scholar
• Vanheel A, Daniels R, Plaisance S, et al. Identification of protein networks involved in the disease course of experimental autoimmune encephalomyelitis: an animal model of multiple sclerosis. PLoS One 2012;7:e35544
   Google Scholar
• Koguchi Y, Buenafe AC, Thauland TJ, et al. Preformed CD40L is stored in Th1, Th2, Th17, and T follicular helper cells as well as CD4+ 8-thymocytes and invariant NKT cells but not in Treg cells. PLoS One 2012;7:e31296
   Google Scholar
• Sulavik MC, Tardif G, Clewell DB. Identification of a gene, rgg, which regulates expression of glucosyltransferase and influences the SPP phenotype of Streptococcus gordonii Challis. J Bacteriol 1992;174:3577–3586
   PubMed Web of Science ®Google Scholar
• Benesova Y, Vasku A, Novotna H, et al. Matrix metalloproteinase-9 and matrix metalloproteinase-2 as biomarkers of various courses in multiple sclerosis. Mult Scler 2009;15:316–322
   PubMed Web of Science ®Google Scholar
• Taupin V, Renno T, Bourbonniere L, et al. Increased severity of experimental autoimmune encephalomyelitis, chronic macrophage/microglial reactivity, and demyelination in transgenic mice producing tumor necrosis factor-alpha in the central nervous system. Eur J Immunol 1997;27:905–913
   PubMed Web of Science ®Google Scholar
• Murphy AC, Lalor SJ, Lynch MA, Mills KH. Infiltration of Th1 and Th17 cells and activation of microglia in the CNS during the course of experimental autoimmune encephalomyelitis. Brain Behav Immun 2010;24:641–651
   PubMed Web of Science ®Google Scholar
• Miller E, Wachowicz B, Majsterek I. Advances in antioxidative therapy of multiple sclerosis. Curr Med Chem 2013;20:4720–4730
   PubMed Web of Science ®Google Scholar
• Zaheer S, Wu Y, Bassett J, et al. Glia maturation factor regulation of STAT expression: a novel mechanism in experimental autoimmune encephalomyelitis. Neurochem Res 2007;32:2123–2131
   PubMedGoogle Scholar
• Lee DH, Gold R, Linker RA. Mechanisms of oxidative damage in multiple sclerosis and neurodegenerative diseases: therapeutic modulation via fumaric acid esters. Int J Mol Sci 2012;13:11783–11803
   PubMed Web of Science ®Google Scholar
• Zindler E, Zipp F. Neuronal injury in chronic CNS inflammation. Best Pract Res Clin Anaesthesiol 2010;24:551–562
   PubMedGoogle Scholar
• Smith KJ, Lassmann H. The role of nitric oxide in multiple sclerosis. Lancet Neurol 2002;1:232–241
   PubMed Web of Science ®Google Scholar
• Moriya M, Nakatsuji Y, Miyamoto K, et al. Edaravone, a free radical scavenger, ameliorates experimental autoimmune encephalomyelitis. Neurosci Lett 2008;440:323–326
   PubMed Web of Science ®Google Scholar
• Mirshafiey A, Ghalamfarsa G, Asghari B, Azizi G. Receptor tyrosine kinase and tyrosine kinase inhibitors: new hope for success in multiple sclerosis therapy. Innov Clin Neurosci 2014;11:23–36
   Google Scholar
• Dos Santos C, McDonald T, Ho YW, et al. The Src and c-Kit kinase inhibitor dasatinib enhances p53-mediated targeting of human acute myeloid leukemia stem cells by chemotherapeutic agents. Blood 2013;122:1900–1913
   PubMed Web of Science ®Google Scholar
• Fujita H, Kitawaki T, Sato T, et al. The tyrosine kinase inhibitor dasatinib suppresses cytokine production by plasmacytoid dendritic cells by targeting endosomal transport of CpG DNA. Eur J Immunol 2013;43:93–103
   Google Scholar
• Brownlow N, Mol C, Hayford C, et al. Dasatinib is a potent inhibitor of tumour-associated macrophages, osteoclasts and the FMS receptor. Leukemia 2009;23:590–594
   PubMed Web of Science ®Google Scholar
• Schieven GL, Zhang R, Pitt S, et al. Dasatinib potential for anti-inflammatory efficacy while avoiding suppression of T cell activation in preclinical models. J Immunol 2009;182:33–38
   Google Scholar
• Porkka K, Koskenvesa P, Lundan T, et al. Dasatinib crosses the blood–brain barrier and is an efficient therapy for central nervous system Philadelphia chromosome-positive leukemia. Blood 2008;112:1005–1012
   PubMed Web of Science ®Google Scholar
• Schade AE, Schieven GL, Townsend R, et al. Dasatinib, a small-molecule protein tyrosine kinase inhibitor, inhibits T-cell activation and proliferation. Blood 2008;111:1366–1377
   PubMed Web of Science ®Google Scholar
• Futosi K, Németh T, Pick R, et al. Dasatinib inhibits proinflammatory functions of mature human neutrophils. Blood 2012;21:4981–4991
   Google Scholar
• Das J, Chen P, Norris D, et al. 2-Aminothiazole as a novel kinase inhibitor template. Structure-activity relationship studies toward the discovery of N-(2-chloro-6-methylphenyl)-2-[[6-[4-(2-hydroxyethyl)-1-piperazinyl)]-2-methyl-4-pyrimidinyl]amino)]-1,3-thiazole-5-carboxamide (dasatinib, BMS-354825) as a potent pan-Src kinase inhibitor. J Med Chem 2006;49:6819–6832
   PubMed Web of Science ®Google Scholar
• Zhang RL, Chopp M, Chen H, Garcia JH. Temporal profile of ischemic tissue damage, neutrophil response, and vascular plugging following permanent and transient (2H) middle cerebral artery occlusion in the rat. J Neurol Sci 1994;125:3–10
   PubMed Web of Science ®Google Scholar
• Jacobs MA, Zhang ZG, Knight RA, et al. A model for multiparametric mri tissue characterization in experimental cerebral ischemia with histological validation in rat: Part 1. Stroke: J Cereb Circul 2001;32:943–949
   Google Scholar
• Grisham MB, Johnson GG, Lancaster JR Jr. Quantitation of nitrate and nitrite in extracellular fluids. Methods Enzymol 1996;268:237–246
   PubMed Web of Science ®Google Scholar
• Mosayebi G, Haghmorad D, Namaki S, et al. Therapeutic effect of EDTA in experimental model of multiple sclerosis. Immunopharmacol Immunotoxicol 2010;32:321–326
   PubMed Web of Science ®Google Scholar
• Benzie IF, Strain JJ. The ferric reducing ability of plasma (FRAP) as a measure of “antioxidant power”: the FRAP assay. Anal Biochem 1996;239:70–76
   PubMed Web of Science ®Google Scholar
• Mosmann T. Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. J Immunol Methods 1983;65:55–63
   PubMed Web of Science ®Google Scholar
• Azizi G, Haidari MR, Khorramizadeh M, et al. Effects of imatinib mesylate in mouse models of multiple sclerosis and in vitro determinants. Iran J Allergy Asthma Immunol 2014;13:198–206
   PubMed Web of Science ®Google Scholar
• Lopez-Diego RS, Weiner HL. Novel therapeutic strategies for multiple sclerosis – a multifaceted adversary. Nat Rev Drug Discov 2008;7:909–925
   PubMed Web of Science ®Google Scholar
• Mirshafiey A, Ghalamfarsa G, Asghari B, Azizi G. Receptor tyrosine kinase and tyrosine kinase inhibitors: new hope for success in MS therapy. Innov Clin Neurosci 2014;11:23–36
   Google Scholar
• Azizi G, Mirshafiey A. Imatinib mesylate: an innovation in treatment of autoimmune diseases. Recent Pat Inflamm Allergy Drug Discov 2013;7:259–267
   PubMedGoogle Scholar
• Fraser CK, Lousberg EL, Kumar R, et al. Dasatinib inhibits the secretion of TNF-alpha following TLR stimulation in vitro and in vivo. Exp Hematol 2009;37:1435–1444
   PubMed Web of Science ®Google Scholar
• Blaise GA, Gauvin D, Gangal M, Authier S. Nitric oxide, cell signaling and cell death. Toxicology 2005;208:177–192
   PubMed Web of Science ®Google Scholar
• Murphy S. Production of nitric oxide by glial cells: regulation and potential roles in the CNS. Glia 2000;29:1–13
   PubMed Web of Science ®Google Scholar
• Fereidoni M, Sabouni F, Moghimi A, Hosseini S. The effects of trypsin on rat brain astrocyte activation. Iran J Neurol 2013;12:129–135
   PubMed Web of Science ®Google Scholar
• Echeverria V, Burgess S, Gamble-George J, et al. Sorafenib inhibits nuclear factor kappa B, decreases inducible nitric oxide synthase and cyclooxygenase-2 expression, and restores working memory in APPswe mice. Neuroscience 2009;162:1220–1231
   PubMedGoogle Scholar
• Fei F, Yu Y, Schmitt A, et al. Dasatinib exerts an immunosuppressive effect on CD8+ T cells specific for viral and leukemia antigens. Exp Hematol 2008;36:1297–1308
   PubMed Web of Science ®Google Scholar
• Cui W, Zhang ZJ, Hu SQ, et al. Sunitinib produces neuroprotective effect via inhibiting nitric oxide overproduction. CNS Neurosci Ther 2014;20:244–252
   Web of Science ®Google Scholar
• Ghalaut VS, Sangwan L, Dahiya K, et al. Effect of imatinib therapy with and without turmeric powder on nitric oxide levels in chronic myeloid leukemia. J Oncol Pharm Pract 2012;18:186–190
   PubMedGoogle Scholar
• Fonseca SG, Romao PR, Figueiredo F, et al. TNF-alpha mediates the induction of nitric oxide synthase in macrophages but not in neutrophils in experimental cutaneous leishmaniasis. Eur J Immunol 2003;33:2297–2306
   PubMed Web of Science ®Google Scholar
• Shiryaev SA, Savinov AY, Cieplak P, et al. Matrix metalloproteinase proteolysis of the myelin basic protein isoforms is a source of immunogenic peptides in autoimmune multiple sclerosis. PLoS One 2009;4:e4952
   PubMed Web of Science ®Google Scholar
• Buettner R, Mesa T, Vultur A, et al. Inhibition of Src family kinases with dasatinib blocks migration and invasion of human melanoma cells. Mol Cancer Res 2008;6:1766–1774
   PubMed Web of Science ®Google Scholar
• Dhawan G, Floden AM, Combs CK. Amyloid-beta oligomers stimulate microglia through a tyrosine kinase dependent mechanism. Neurobiol Aging 2012;33:2247–2261
   PubMed Web of Science ®Google Scholar
• Lindauer M, Hochhaus A. Dasatinib. Recent results in cancer research Fortschritte der Krebsforschung. Prog Cancer Res 2014;201:27–65
   Google Scholar